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ABSTRACT
Background: Although interleukin (IL)-12, IL-10 and
interferon (IFN)-γ are key cytokines that control the T
helper (Th) 1/Th2 balance in human allergic dis-
orders, details of their interactions in humans have not
been clarified. Recently IL-10, one of the Th2 cyto-
kines, has been shown to have an anti-inflammatory
effect against allergic responses. To clarify the effect of
IL-12 on the production of IFN-γ and IL-10, in the
present study we examined responses of peripheral
blood mononuclear cells (PBMC) from asthmatics to
stimulation by Dermatophagoides farinae (Df) antigen
in the presence of exogenous IL-12.
Methods: Peripheral blood mononuclear cells of
Df-sensitized (n = 7) and non-sensitized (n = 5) asth-
matics were stimulated by Df antigen after incubation
with exogenous IL-12 (100 pg/mL). Interferon-γ and
IL-10 produced in culture supernatants were measured
by ELISA. The effect of IL-12 on lymphocyte prolifera-
tion was assayed by [3H]-thymidine incorporation in
both groups.
Results: The production of IFN-γ by PBMC was signif-
icantly enhanced by incubation with IL-12 in both
patient groups (P < 0.05), while IL-12 did not affect
the production of IL-10 in either group. Lymphocyte
proliferation induced by Df antigen was significantly
higher in the Df-sensitized group (P < 0.01). This
lymphocyte proliferation was significantly enhanced 
by exogenous IL-12 only in the Df-sensitized group 
(P < 0.05).
Conclusions: These observations indicate that IL-12
enhances Th1-shifted immune responses without
affecting IL-10 production and suggest that IL-12 may
effectively inhibit the Th2 dominant state of bronchial
asthma by regulating the Th1/Th2 balance.
Key words: bronchial asthma, Dermatophagoides
farinae, interferon-γ, interleukin-10, interleukin-12,
peripheral blood mononuclear cells.
INTRODUCTION
Allergic inflammation is mainly mediated by CD4+ T
lymphocytes producing T helper (Th) 2-type cytokines,
such as interleukin (IL)-4 and IL-5. Because both mRNA
and protein levels of these cytokines are elevated in
bronchial wall and bronchoalveolar lavage (BAL) cells in
asthmatics,1 bronchial asthma is thought to be caused 
by deviation to a Th2 dominant immune response.
Interleukin-4 is an essential factor for IgE switching and
enhances inappropriate IgE synthesis.2 Interleukin-5 has
selective biological effects on eosinophils and their pre-
cursors and promotes accumulation of eosinophils into
the bronchial mucosa in asthmatics.3 In contrast, allergic
inflammation is inhibited by interferon (IFN)-γ, which is
one of the Th1 cytokines, and IFN-γ has been shown to
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suppress both IgE class switching and the proliferation of
Th2 cells.4,5
Recently, IL-12, which is a heterodimeric cytokine pri-
marily produced by monocytes and macrophages,6 has
been shown to be a key cytokine modulating differentia-
tion of Th0 cells to Th1 cells.7 Because IL-12 is a potent
inducer of IFN-γ8,9 and a suppressor of IL-4, IL-5 and
IgE,10–13 an immunomodulatory role of IL-12 has been
investigated in allergic animal models. Interleukin-12
inhibited antigen-induced airway hyperresponsiveness
and eosinophil recruitment into the airway mucosa in
murine models.14–17 Therefore, IL-12 may have a bene-
ficial role in the treatment of bronchial asthma by
suppressing Th2 responses.
Interleukin-10 was initially characterized as a Th2
cytokine that could inhibit IFN-γ production and suppress
Th1 cell development in murine systems,18,19 but recent
studies have shown that IL-10 also has potent anti-
inflammatory activities in immune responses.20–24 Moreover,
BAL fluid (BALF) from asthmatics contained less IL-10
than BALF from normal subjects.25 Thus, IL-10 has the
potential for preventing allergic inflammation and sup-
pression of IL-10 may cause exacerbation of allergic
diseases. The effect of IL-12 on the production of IL-10 
is still controversial.26,27 Accordingly, to elucidate the
immunomodulatory effect of IL-12 on the Th1/Th2
balance in allergic disorders, we investigated antigen-
induced lymphocyte proliferation and production of
IFN-γ and IL-10 in the presence of IL-12 in asthmatics
sensitized by Dermatophagoides farinae (Df). We found
that IL-12 enhanced IFN-γ production in Df-sensitized
and non-sensitized patients and that Df-antigen-induced
lymphocyte proliferation was enhanced by exogenous
IL-12 in Df-sensitized patients.
METHODS
Subjects
We studied 12 adult patients with mild or moderate
asthma, who met the criteria of the Japanese Society of
Allergology and the American Thoracic Society,28 and
also five healthy subjects (median age 42 years; age
range 38–50 years). None of the patients required
regular oral steroid medications. The patient group
included seven Df-sensitized asthmatics (median age 
41 years; age range 25–56 years) and five who were 
Df-non-sensitized asthmatics (median age 50 years; 
age range 39–64 years). The Df-sensitized asthmatics
were characterized by positive immediate skin reactions
(positive response ≥ 10 mm mean diameter) to dust mite
antigen (Torii Pharmaceuticals, Tokyo, Japan) and posi-
tive scores for the radioallergosorbent test (RAST) to 
Df antigen. A RAST score > 1 was considered to be pos-
itive on a scale of 0–4. The Df-non-sensitized asthmatics
were defined as those negative for immediate skin reac-
tions and RAST. Peripheral blood was collected when
there were no symptoms of asthma. Informed consent
was obtained from all patients prior to their participation
in this study.
Cell preparation and culture
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized venous blood by density gradient
centrifugation on Histopaque (Sigma Chemical Co., 
St Louis, MO, USA). Cell viability was > 98%, as deter-
mined by Trypan blue dye exclusion. Peripheral blood
mononuclear cells were resuspended in RPMI 1640
supplemented with 5% heat-inactivated fetal calf serum
(FCS), glutamine (2 mmol/L), penicillin (100 units/mL)
and streptomycin (100 µg/mL).
Antigen
Crude Df extract was provided by Torii Pharmaceuticals.
The Df antigen was used at a concentration of 10 µg/mL,
which was found to be an optimal concentration for the
induction of PBMC proliferation and cytokine production
in preliminary experiments (data not shown) and is also
based on a concentration used in a previous report.29
Proliferation assay
Peripheral blood mononuclear cells (1 × 105 /well) were
cultured in triplicate in 96-well flat-bottomed plates
(Corning; Costar, Corning, NY, USA) in medium alone or
with Df antigen in the presence or absence of IL-12 
(100 pg/mL; Genetics Institute, Cambridge, MA, USA) at
37°C in a humidified atmosphere with 5% CO2 in air.
After 3 days culture, PBMC were pulsed with 37 kBq 
[3H]-thymidine (Amersham Japan, Tokyo, Japan) to each
well. Eighteen hours later, cells were harvested and their
filter-associated radioactivity was determined with a
liquid scintillation counter. The incubation time used in
the present study was based on that in a previous
report.27 Proliferative responses were evaluated with a
stimulation index (SI), which was calculated as follows:
SI = (mean c.p.m. of the test culture/mean c.p.m.
of the control culture)
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Cytokine production
To study the effect of exogenous IL-12 on Df antigen-
induced production of IFN-γ and IL-10, PBMC were
incubated with or without Df antigen (10 µg/mL) in 
24-well culture plates in the presence or absence of
recombinant human IL-12. Fifteen minutes before the
addition of Df antigen, IL-12 was added to cultures at a
final concentration of 100 pg/mL. To rule out the effect of
endogenous IL-12, a neutralizing test was also performed
with an anti-IL-12 monoclonal antibody (mAb; R&D
Systems, Minneapolis, MN, USA). According to the appli-
cation note, the Neutralization Dose50 (ND50) for this
anti-IL-12 mAb has been determined to be approximately
0.3–0.9 µg/mL, using the human phytohemagglutinin-
activated PBMC proliferation assay. An anti-IL-12
antibody was added, with the final concentration ranging
from 0.1 to 10 µg/mL. Supernatants were collected after
48 h incubation and were kept at –70°C until measure-
ment of cytokines. The production of IFN-γ and IL-10 in
the supernatants gradually increased for up to 48 h, and
then plateaued. Concentrations of IFN-γ and IL-10 were
determined by ELISA assays (Endogen, Boston, MA,
USA). Detection limits for IL-10 and IFN-γ were 2 and 
3 pg/mL, respectively.
Statistical analysis
All results are presented as the mean ± SEM. Data were
analyzed statistically by using two-tailed Student’s t-test or
paired t-test. Significant differences were indicated when
P < 0.05.
RESULTS
Production of IFN-γ and IL-10 from Df antigen-
stimulated PBMC
Because IL-12 could be detected in the supernatant of 
Df antigen-stimulated PBMC of Df-sensitized asthmatics
in preliminary experiments at concentrations less than 
20 pg/mL (data not shown) and high concentrations of
IL-12 were shown to cause serious toxicity in a previous
report,30 IL-12 was added at concentrations ranging from
0.1 to 100 pg/mL. The results showed that IFN-γ produc-
tion from Df antigen-stimulated PBMC was affected by
the addition of IL-12 in a dose-dependent manner 
(Fig. 1). However, IL-10 production was not affected by
exogenous IL-12. From these observations, the concen-
tration of IL-12 used was set at 100 pg/mL in the
following experiments.
Proliferative responses induced by Df antigen
The Df-sensitized asthmatics showed higher proliferative
responses to Df antigen than non-sensitized asthmatics
when responses were compared by SI (1.80 ± 0.50 vs
0.94 ± 0.52, respectively; P < 0.01; Fig. 2). The SI
value for healthy subjects was 1.03 ± 0.21 (n = 5; data
not shown).
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Fig. 1 (a) Interferon (IFN)-γ production and (b) interleukin (IL)-10 production from peripheral blood mononuclear cells of
asthmatics incubated with 10 µg/mL Dermatophagoides farinae (Df) antigen for 48 h. Data are the mean ± SEM of three experi-
ments. *P < 0.05 compared with control.
Effect of IL-12 on the production of IFN-γ
and IL-10
The concentration of IFN-γ produced by Df-stimulated
PBMC from Df-sensitized asthmatics in the presence or
absence of IL-12 was 755.16 ± 261.70 and 88.86
± 47.26 pg/mL, respectively. Similarly, in non-sensitized
asthmatics, the concentration of IFN-γ produced was
higher in the presence than the absence of IL-12 (555.50
± 258.03 vs 17.06 ± 8.64 pg/mL, respectively). In
healthy subjects, the concentration of IFN-γ produced in
the presence or absence of IL-12 was 532.02 ± 89.75
and 11.93 ± 3.98 pg/mL, respectively (Fig. 3a). Although
values fluctuated considerably from case to case in all
groups, the differences in cytokine production were
significantly different between the presence and absence
of IL-12 (P < 0.05). The production of IL-10 by Df-
stimulated PBMC was not significantly affected by 
100 pg/mL IL-12 for all Df-sensitized asthmatics (131.15
± 21.5 vs 126.79 ± 26.17 pg/mL for the absence vs
presence of IL-12, respectively), non-sensitized asthmat-
ics (96.03 ± 19.00 vs 109.21 ± 27.44 pg/mL for the
absence vs presence of IL-12, respectively) and healthy
subjects (176.95 ± 20.87 vs 178.98 ± 33.34 pg/mL
for the absence vs presence of IL-12, respectively; 
Fig. 3b). The production of IFN-γ and IL-10 under in the
presence of IL-12 without Df antigen stimulation showed
lower concentrations of cytokines produced compared
with production following stimulation of PBMC with 
Df antigen. The production of IFN-γ in Df-sensitized
asthmatics, non-sensitized asthmatics and healthy 
subjects was 10.73 ± 3.14, 5.13 ± 1.70 and 2.71 ±
1.18 pg/mL, respectively, while the production of IL-10 in
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Fig. 2 Proliferative response of peripheral blood mono-
nuclear cells (PBMC) from Dermatophagoides farinae (Df)-
sensitized and non-sensitized asthmatics. The PBMC were
incubated for 3 days with 10 µg/mL Df antigen and were then
pulsed with [3H]-thymidine and harvested after 18 h of addi-
tional culture. Data are expressed as stimulation index (SI).
Each line represents the change in individual donors. The mean
of the data in each category is indicated by the horizontal line.
Fig. 3 (a) Interferon (IFN)-γ production and (b) interleukin (IL)-10 production from peripheral blood mononuclear cells of
Dermatophagoides farinae (Df)-sensitized (; n = 7) and non-sensitized ( ; n = 5) asthmatics stimulated with 10 µg/mL Df
antigen in the presence or absence of 100 pg/mL IL-12. (), healthy subjects. Data are the mean ± SEM. *P < 0.05.
these same groups was 9.99 ± 2.63, 6.70 ± 1.55 and
9.40 ± 2.37 pg/mL, respectively.
Effect of IL-12 on proliferative responses
Proliferative responses of PBMC stimulated by Df antigen
in Df-sensitized asthmatics in the absence or presence of
IL-12 were 1.80 ± 0.50 and 2.22 ± 0.21 SI, respec-
tively. Exogenous IL-12 significantly enhanced pro-
liferation of PBMC in Df-sensitized asthmatics (P < 0.05;
Fig. 4a). However, in non-sensitized asthmatics, prolifer-
ative responses of PBMC in the absence or presence of
IL-12 were 0.94 ± 0.52 and 1.32 ± 0.16 SI, respec-
tively, and there was no significant difference between
these two groups (Fig. 4b).
Neutralizing test of IL-12
To rule out the effect of endogenous IL-12, we performed
a neutralizing test by adding an anti-IL-12 antibody to
cultures examining the production of IFN-γ or IL-10 by
Df-stimulated PBMC. The production of IFN-γ by PBMC
stimulated with Df antigen in the presence of IL-12 was
inhibited by the addition of an anti-IL-12 antibody in 
a dose-dependent manner (Fig. 5). At a concentration 
of 10 µg/mL, the anti-IL-12 antibody inhibited IFN-γ
production almost completely (> 95% inhibition). The
production of IFN-γ by Df stimulated PBMC in the
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Fig. 4 Proliferative response of peripheral blood mononuclear cells (PBMC) from (a) Dermatophagoides farinae (Df)-sensitized 
(n = 7) and (b) non-sensitized (n = 5) asthmatics. The PBMC were incubated for 3 days with 10 µg/mL Df antigen (Ag) in the pres-
ence or absence of 100 pg/mL interleukin (IL)-12. Cells were pulsed with [3H]-thymidine and harvested after 18 h of additional
culture. Results are expressed as stimulation index (SI).
Fig. 5 Neutralizing test for interleukin (IL)-12 using anti-IL-12
antibody for interferon (IFN)-γ production. Peripheral blood
mononuclear cells from Dermatophagoides farinae (Df)-
sensitized asthmatics were incubated with Df antigen and/or
100 pg/mL of IL-12 and/or three different concentrations of anti-
IL-12 antibody (Ab) for 48 h. Data are the mean ± SEM of three
experiments. *P < 0.05 compared with the group incubated
with Df and IL-12 (). ( ), Df + IL-12 + 0.1 µg/mL αIL-12Ab;
( ), Df + IL-12 + 1.0 µg/mL αIL-12Ab; ( ), Df + IL-12 +
10 µg/mL αIL-12Ab; (), Df + 10 µg/mL αIL-12Ab; ( ), Df.
absence or presence of anti-IL-12 antibody was 62.9
± 28.0 and 14.0 ± 3.1 pg/mL, respectively. Anti-IL-12
antibody could inhibit IFN-γ production to the same
degree (13.4 ± 4.7 pg/mL) in the presence of IL-12.
Because 10 µg/mL anti-IL-12 antibody neutralized
exogenous IL-12 and completely inhibited IFN-γ produc-
tion, IFN-γ production was largely induced by exogenous
IL-12 in this system (Fig. 6a). Although IL-10 production
from Df antigen-stimulated PBMC showed a tendency to
decrease in the presence of IL-12 and to be increased in
the presence of an anti-IL-12 antibody, the difference
between these two conditions was not significant. The
production of IL-10 by Df antigen-stimulated PBMC was
not significantly affected by neutralizing both endoge-
nous and exogenous IL-12 (Fig. 6b).
DISCUSSION
In the present study, we examined the effect of IL-12 on
PBMC stimulated by Df antigen in both Df-sensitized 
and non-sensitized asthmatics. We demonstrated that 
Df-sensitized asthmatics showed greater lymphocyte
proliferation in response to Df antigen compared with
non-sensitized asthmatics. Interleukin-12 significantly
enhanced not only lymphocyte proliferation, but also
IFN-γ production when PBMC were stimulated with Df
antigen in Df-sensitized asthmatics. However, in non-
sensitized asthmatics, IL-12 enhanced only IFN-γ
production and failed to enhance lymphocyte prolifera-
tion. These results suggest that IL-12 can induce both
resting and activated T cells to produce IFN-γ, while
enhanced lymphocyte proliferation was observed only in
activated T cells in sensitized asthmatics. Previous reports
have shown that IL-12 enhances proliferation of PBMC or
lymphocytes when they are activated by antigen.31–33
Recent evidence indicates that only activated T cells
express receptors for IL-1234 and antigen stimulation
induces upregulation of IL-12 receptors on T cells, which
allows an increased proliferative response to IL-12.35
These data could be the reason why, in the present study,
lymphocytes of Df-sensitized asthmatics stimulated by Df
antigen showed a higher proliferation response in the
presence of IL-12 compared with non-sensitized asthmat-
ics. Furthermore, IL-12 did not increase lymphocyte
proliferation in non-sensitized asthmatics, whereas it did
increase IFN-γ production from PBMC. This dissociation
between lymphocyte proliferation and IFN-γ production
could not be explained by the regulation of the IL-12
receptor. However, because we showed that IFN-γ pro-
duction under conditions in which the PBMC were not
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Fig. 6 Neutralizing test for interleukin (IL)-12 on the production of (a) interferon (IFN)-γ and (b) IL-10. Peripheral blood mono-
nuclear cells from Dermatophagoides farinae (Df)-sensitized asthmatics were incubated with Df antigen and/or 100 pg/mL of IL-12
and/or 10 µg/mL anti-IL-12 antibody (Ab) for 48 h. Data are the mean ± SEM of five experiments. *P < 0.05 compared with the
group incubated with Df and IL-12.
stimulated by Df antigen in the presence of IL-12 were
apparently lower than those when PBMC were stimulated
by Df antigen, antigen stimulation was indispensable for
the production of IFN-γ. This result indicates that the
main source of IFN-γ may be activated T cells. Taken
together, our data suggest that IL-12 may induce a potent
Th1-type immune reaction in both Df-sensitized and non-
sensitized asthmatics and, after that, it may regulate Df
antigen-induced Th2-type immune responses.
In a murine system, intraperitoneal administration of
IFN-γ has been shown to decrease antigen-induced
CD4+ T cells and to prevent eosinophil infiltration 
into tracheal mucosa.36 This observation indicates that 
IFN-γ inhibits antigen-induced eosinophil recruitment
into tissue by inhibiting Th2 cell infiltration. Other murine
studies have shown that intraperitoneal administration 
of IL-12 suppresses airway eosinophilia14 and hyper-
responsiveness15,37 without affecting IgE production.16
Furthermore, intranasal IL-12 administration has been
reported to suppress eosinophil infiltration into the lung
and airway hyperresponsiveness.17 Another in vivo study
has shown that successful immunotherapy increases 
IL-12 mRNA-positive cells at allergen-challenged sites.38
Moreover, reduced production of IL-12 or lack of IL-12
signaling in allergen-specific Th2 cells has been
observed in allergic patients.39,40 Because the inhibitory
effect of IFN-γ on Th2 cells is enhanced by IL-12, it may
be useful in suppressing allergic inflammation.4,5 Thus,
exogenous IL-12 could play a therapeutic role in the
treatment of bronchial asthma.
Previously, IL-10 was recognized as a Th2 cytokine18,19
because it inhibited Th1-induced delayed-type hyper-
sensitivity41 and exacerbated Th2-type allergic inflam-
mation.42 Recently, an anti-inflammatory function of 
IL-10 has been demonstrated in immune responses.20–23
Interleukin-10 inhibited cytokine generation from mast
cells43 and both survival and cytokine production of
eosinophils.44 It was also shown that IL-10 induced 
an antigen-specific anergic state in CD4+ T cells.23
Successful antigen-specific immunotherapy upregulated
IL-10 production in bee venom allergy and caused
antigen-specific anergy in peripheral T cells.45 Moreover,
BALF from asthmatics showed that constitutive production
of IL-10 was diminished in asthmatics compared with
normal controls;25 inhaled corticosteroids increased IL-
10 production by alveolar macrophages in asthmatics.46
Because impaired IL-10 production permits the release of
proinflammatory cytokines and leads to the development
of bronchial inflammation in asthmatics, IL-10 may retain
the potential to reduce allergic bronchial inflammation.47
We have shown that IL-12, at a dose of 100 pg/mL, did
not affect IL-10 production in either Df-sensitized or non-
sensitized asthmatics. This concentration of IL-12 was
10–100-fold lower than those used in previous studies.
In the present study, we used preferentially lower doses
of IL-12 because high doses of IL-12 have been reported
to exert severe toxicities in an in vivo study.30 The results 
of an IL-12 neutralizing test indicated that endogenous 
IL-12 was negligible and 100 pg/mL exogenous IL-12
was enough to regulate the production of IFN-γ. In addi-
tion, in the present study, the concentrations of IL-10 
in asthmatic groups were lower than those in healthy
subjects. This result indicates the possibility that lower
production of IL-10 may induce prolonged allergic
inflammation in asthmatic groups.
Regulation of IL-10 by IL-12 has been examined by
other investigators and their results were different from
ours because of different methods used or study con-
ditions. Several studies have shown that IL-12 inhibits the
production of IL-10,27,48 while others have found that 
IL-12 induces IL-10 production by T cells.26,49,50 These
studies were performed with T cell lines or T cell clones,
which aimed to clarify the immunologic functions of 
T cells in the presence of IL-12. To evaluate the whole
immunologic reaction of immunocomponent cells,
including T cells and antigen-presenting cells, we exam-
ined lymphocyte proliferation and the production of
cytokines in a bulk culture system. Because the produc-
tion of IL-10 is influenced by the culture conditions,
regulatory mechanisms of IL-10 remain to be studied
further.
Glucocorticoids (GC) are most important agents for
the treatment of allergic inflammation. Physiologic
concentrations of exogenous GC can inhibit IL-12 pro-
duction, but do not affect IL-10 production in vitro.51 It
has been shown that GC affect the function of antigen-
presenting cells to develop Th2 lymphocytes.52 From
these reports, GC are considered to possibly supporting
Th2 development. Our data imply that immunomodula-
tors, such as IL-12, could be used as complementary
agents to GC to avoid shifting to a Th2 dominant
immune reaction. Because exogenous systemic IL-12
administration has been shown to induce severe adverse
effects in a clinical trial,30 inhaled administration of 
IL-12 may be better than systemic administration because
this method of administration will be able to provide 
a sufficient local IL-12 concentration without any ad-
verse systemic effects. According to our results, because 
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low-dose IL-12 still has a preferable effect on allergic
inflammation, inhalational administration of IL-12 may
be an effective method of treatment.
In summary, our results suggest that low-dose IL-12
enhances IFN-γ production but does not inhibit IL-10
production when PBMC are stimulated by Df antigen.
Because IFN-γ can suppress Th2 dominant allergic
immune reactions and IL-10 can inhibit hyperactivation
of sensitized lymphocytes, low-dose IL-12 could be a
useful candidate therapeutic agent for the treatment of
bronchial asthma.
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